Racemic bupivacaine is the most common local anaesthetic used intrathecally. This prospective, randomized, doubleblind study compared the clinical efficacy and motor block of 0.5% levobupivacaine with 0.5% racemic bupivacaine in spinal anaesthesia for urological surgery. The surgery required an upper level of sensory block of at least the tenth thoracic dermatome. Fifty patients were recruited (levobupivacaine group n=24; bupivacaine group n=26). Spinal anaesthesia was achieved with 2.6 ml of study solution injected in the subarachnoid space at the lumbar 3/4 interspace. One patient from the levobupivacaine group was excluded due to technical failure. There were no significant differences between the two groups in the quality of sensory and motor block or in haemodynamic change. Anaesthesia was adequate and patient satisfaction good in all cases.
Due to its long duration of action, racemic bupivacaine is one of the commonest local anaesthetics used. However, profound myocardial depression and even cardiac arrest can occur after accidental intravascular injection. Resuscitation from bupivacaineinduced cardiovascular collapse has been found to be difficult and may be unsuccessful 1, 2 . Levobupivacaine is the S(-)-enantiomer of racemic bupivacaine. The cardiotoxicity of levobupivacaine is less than that of racemic bupivacaine, due to the lower affinity of the S(-) isomer than the R(+) isomer for the inactivated state of the cardiac sodium channel 3 . In view of this potential decrease in cardiotoxicity, levobupivacaine appears to be an attractive alternative to racemic bupivacaine. Clinical studies comparing levobupivacaine and racemic bupivacaine in epidural and infiltration anaesthesia show that both are equally effective [4] [5] [6] [7] [8] . At the time of designing this study there were only four published trials of intra-thecal administration of levobupivacaine. The results on clinical efficacy and motor block were not consistent [9] [10] [11] [12] . The first publication was a non-comparative study using 0.5% levobupivacaine for lower limb surgery 9 . The second was a randomized controlled trial of 0.5% levobupivacaine versus racemic bupivacaine for spinal anaesthesia in hip replacement surgery 10 . The other two studies compared hyperbaric 0.25% levobupivacaine and 0.125% levobupivacaine with racemic bupivacaine 11, 12 . No study had investigated 0.5% levobupivacaine for spinal anaesthesia for lower abdominal or urological surgery. Therefore we performed this clinical trial to investigate the clinical efficacy and motor block of 0.5% levobupivacaine and 0.5% racemic bupivacaine in spinal anaesthesia for urological surgery requiring sensory block to at least the tenth thoracic (T10) dermatome.
MATERIALS AND METHODS
This prospective, randomized, double-blind trial was approved by the Ethics Committee, Kwong Wah Hospital. Fifty patients scheduled for elective transurethral resection of the prostate and/or bladder tumour were recruited after giving written informed consent.
The inclusion criteria were (i) age 50 to 75 years, (ii) ASA status 1-3, (iii) body weight 45-80 kg. The exclusion criteria were (i) known hypersensitivity to amide local anaesthetic, (ii) contraindication to spinal anaesthesia, (iii) lack of understanding of English or Chinese.
The patients were randomly assigned into one of two groups, receiving 2.6 ml of an isobaric solution of either 0.5% levobupivacaine or 0.5% racemic bupivacaine intrathecally, according to a computergenerated randomization table. Diazepam 5 mg was given orally at least two hours before surgery as premedication and an intravenous (IV) infusion of Hartmann's solution 10 ml/kg given immediately before spinal anaesthesia. The insertion of the spinal needle was performed under aseptic conditions with the patient in left lateral position. A 25 gauge Quincke needle was used at L3/4 with a midline or paramedian approach. To standardize the technique, the second author (KM) performed all blocks. The patients were turned supine immediately after injection of the spinal drug and were given supplementary nasal oxygen 2 l/min.
Parameters monitored included (i) continuous electrocardiogram, heart rate and pulse oximetry, (ii) non-invasive blood pressure before the conduct of spinal anaesthesia, then every 2.5 minutes for 15 minutes and every 5 minutes thereafter, (iii) sensory block, which was monitored using loss of sensation to cold spray (ethyl chloride) every 2.5 minutes for 15 minutes after the initiation of spinal anaesthesia and at the end of operation, (iv) motor block, assessed according to a modified Bromage scale (0=no paralysis, able to flex hip/knees/ankles; 1=able to flex knees, unable to raise extended legs; 2=able to flex ankles, unable to flex knees; 3=unable to flex ankle, knee and hip) every 2.5 minutes for 15 minutes and at the end of the operation 13 .
The operation was started 15 minutes after the initiation of spinal anaesthesia if the level of sensory block had reached T10 or above. If the level of analgesia was inadequate, general anaesthesia was to be given.
Hypotension was defined as a systolic blood pressure less than 100 mmHg or a decrease of more than 30% from baseline and was treated with incremental doses of ephedrine 5 mg IV and/or intravenous Hartmann's solution. Bradycardia was defined as a heart rate <50 beats per minute and was treated with atropine 0.3-0.6 mg IV.
The onset of adequate sensory block was defined as the time interval from completion of the spinal drug injection to the achievement of a sensory block at T10. The incidence of motor block at the start and end of the operation and the addition of any sedative drug were recorded. At the end of surgery, the patient's satisfaction was assessed as good, fair or poor. The adequacy of anaesthesia was assessed as good, fair or inadequate by the attending anaesthetist.
The sample size was calculated to provide 80% power to detect a 25% reduction in the incidence of complete motor block in the levobupivacaine group compared with the bupivacaine group. Statistical analyses were performed using Student's t-test (for parametric data) and Chi-squared or Fisher's exact tests (for frequency data such as incidence). A significance level of 5% was considered statistically significant.
RESULTS
Fifty patients were recruited (levobupivacaine group n=24; bupivacaine group n=26). One patient in the levobupivacaine group was excluded due to technical failure, with no evidence of sensory and motor block at 30 minutes after intrathecal injection. There were no significant differences between the levobupivacaine and bupivacaine groups for demographic data, baseline haemodynamic parameters, ASA classification or type of operation ( Table 1 , 2).There were no significant differences between the two groups in the quality of sensory and motor block or in haemodynamic change (Tables 3, 4 ).
Side-effects of anaesthesia were infrequent and minor. The incidence of hypotension was 4% (2/49) with both cases in the bupivacaine group. Three patients (levobupivacaine group n=2 and bupi- vacaine group n=1) experienced shivering. One patient in the bupivacaine group had nausea and vomiting. The efficacy of both levobupivacaine and bupivacaine was good. Anaesthesia was adequate and patient satisfaction good in all cases. Two patients in the bupivacaine group and one patient in the levobupivacaine group required sedation with midazolam 1 mg IV in the intraoperative period.
DISCUSSION
This study found that 0.5% levobupivacaine was an effective local anaesthetic for spinal anaesthesia for urological surgery that required a sensory block to the T10 dermatome. The onset time, degree of sensory and motor block and haemodynamic changes were similar to those for 0.5% racemic bupivacaine.
The use of levobupivacaine for other routes of administration, including epidural anaesthesia and nerve plexus blocks, indicates that the anaesthetic potency of levobupivacaine is similar to racemic bupivacaine, although it produces more sustained sensory and motor block [4] [5] [6] [7] [8] . Lyons et al reported that the potency ratio of levobupivacaine to racemic bupivacaine was 0.98 for epidural analgesia for labour pain 8 . Levobupivacaine administered via these routes has the advantage of less cardiotoxicity should accidental intravascular injection occur. Since the dose of bupivacaine used in spinal anaesthesia is small, the issue of cardiotoxicity is less important. Nevertheless, investigation of the clinical effects of intrathecal levobupivacaine is important, because there is the possibility of accidental intrathecal injection during epidural anaesthesia. Furthermore, if levobupivacaine completely replaces racemic bupivacaine for other routes of administration, demand for racemic bupivacaine may drop, such that it may cease to be manufactured for economic reasons.
There are only a few studies involving intrathecal levobupivacaine. Burke et al conducted an open, non-comparative study of 0.5% levobupivacaine 3 ml for spinal anaesthesia for lower limb surgery in twenty patients 9 . The quality of anaesthesia was adequate in only 90% (18/20) of cases. They concluded that the spread of the 0.5% levobupivacaine solution was unpredictable. It was suggested that the variable sensory block might have been due to the hypobaric property of 0.5% levobupivacaine at 37°C 14 . Glaser et al performed a prospective, randomized, double-blind study comparing 0.5% levobupivacaine and racemic bupivacaine 3.5 ml for spinal anaesthesia for elective hip replacement 10 . They found similar clinical effects, including sensory and motor block. Vercauteren et al used 2 ml of 0.125% levobupivacaine or racemic bupivacaine as the initial subarachnoid injection for combined spinal-epidural analgesia in labour 11 . They found similar clinical effects except that levobupivacaine produced no motor block, compared with 34% of patients in the bupivacaine group having motor block equivalent to grade 1 Bromage score. Clinical studies of epidural levobupivacaine also suggest that motor block with levobupivacaine may be less than that of an equivalent dose of racemic bupivacaine. Cox et al compared epidural 0.5% levobupivacaine or bupivacaine for lower limb surgery 7 . They found a trend towards less motor block with an equivalent dose of levobupivacaine. Convery et al compared 0.125% levobupivacaine and 0.125% racemic bupivacaine for epidural analgesia during labour and noted a trend towards less motor block with levobupivacaine 15 early ambulation after spinal anaesthesia in day surgery. Confirmation and determination of optimal doses and concentrations of levobupivacaine requires further study. Alley et al conducted a randomized, double-blind, cross-over study in eighteen healthy volunteers to compare 0.25% hyperbaric levobupivacaine and racemic bupivacaine in doses of 4 to 12 mg for spinal anaesthesia 12 . Levobupivacaine and racemic bupivacaine showed equivalent efficacy in terms of sensory and motor block. Ropivacaine is the S(-)-enantiomer of the propyl analogue of bupivacaine and is also less cardiotoxic than racemic bupivacaine. Its lower lipid solubility potentially confers greater differential block of sensory and motor fibres 16 but it is less potent than bupivacaine in epidural anaesthesia 17 . The equipotent ratio with bupivacaine has not been defined for the intrathecal route but McDonald et al reported it was half as potent as bupivacaine as a 0.25% hyperbaric solution 18 and Gautier et al that ropivacaine 12 mg was equipotent to bupivacaine 8 mg in isobaric solution 19 . The efficacy of isobaric ropivacaine for spinal anaesthesia for urological and abdominal operations appears disappointing. Intrathecal ropivacaine 15 mg was associated with inadequate anaesthesia in 16% of patients having transurethral resection of the bladder or prostate and in 20% of patients undergoing abdominal surgery 20, 21 . Whiteside et al found that hyperbaric 0.5% ropivacaine 3 ml provided reliable spinal anaesthesia for a shorter duration than did hyperbaric 0.5% bupivacaine 3 ml 22 . They stressed that intrathecal ropivacaine needed to be administered as a hyperbaric solution to produce reliable spinal anaesthesia. Reduced motor block is also controversial. Malinovsky et al found similar motor block after 0.3% ropivacaine 15 mg and 0.2% bupivacaine 10 mg given intrathecally 20 , while McNamee et al found a shorter duration of complete motor block and sensory block from 17.5 mg of 0.5% ropivacaine in comparison with the same dose of bupivacaine 23 . Nevertheless, Ogun et al found that in obstetric patients, intrathecal ropivacaine 15 mg had a shorter duration of motor block and a similar duration of sensory block when compared with the same dose of bupivacaine 24 . It is uncertain whether there is a real difference in the clinical profile of the block or just a difference in potency between the two drugs.
Most anaesthetists have extensive experience with intrathecal bupivacaine but the relative intrathecal potency for levobupivacaine, ropivacaine and bupivacaine is not known. The clinical use of levobupivacaine or ropivacaine as isobaric or hyperbaric solutions to replace racemic bupivacaine for spinal anaesthesia requires further evaluation. Levobupivacaine has been licensed for intrathecal use, but hyperbaric solutions of levobupivacaine or ropivacaine are not commercially available.
In conclusion, we found 2.6 ml of 0.5% levobupivacaine to be effective for spinal anaesthesia in urological surgery requiring sensory block to at least the T10 dermatome. This was consistent with Glaser et al 10 but differed from Burke et al 9 who reported unpredictable spread of intrathecal 0.5% levobupivacaine. We believe the larger sample size and randomized controlled design of our study and that of Glaser et al better reflect the clinical picture. This study supports that 0.5% levobupivacaine is an effective alternative to racemic bupivacaine in spinal anaesthesia for surgery that requires a sensory block to at least T10.
